• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

己酮可可碱疗法在口腔黏膜下纤维化治疗中的应用

Pentoxifylline therapy in the management of oral submucous fibrosis.

作者信息

Mehrotra Ravi, Singh H P, Gupta S C, Singh M, Jain S

机构信息

Departments of Pathology, MLN Medical College and SRN Hospital, Allahabad, India.

出版信息

Asian Pac J Cancer Prev. 2011;12(4):971-4.

PMID:21790236
Abstract

OBJECTIVES

Oral submucous fibrosis is a common premalignant condition in the Indian subcontinent and is caused by chewing areca nut and other irritants in various forms. Its medical treatment is not yet fully standardized. In this study we compared the efficacy of Pentoxifylline as compared to placebo.

MATERIALS AND METHODS

75 patients suffering from oral submucous fibrosis were randomly divided into two groups A and B. Group A patients received placebo, while Group B patients received 400 mg. Pentoxifylline for a period of 7 months. Treatment outcome was evaluated on the basis of improvement in symptom and sign scores. Student's t test was applied for comparing the results.

RESULTS

The improvement in total (i.e. symptoms + sign) score was 25% in group A and 49.15% in group B. This difference was found to be statistically significant. (p < 0.05)

CONCLUSION

Treatment regimen of group B was more effective. No significant side effects were seen. A follow up study is required to assess long term outcome of this therapy.

摘要

目的

口腔黏膜下纤维化是印度次大陆一种常见的癌前病变,由咀嚼槟榔及其他各种形式的刺激物引起。其医学治疗尚未完全标准化。在本研究中,我们比较了己酮可可碱与安慰剂的疗效。

材料与方法

75例口腔黏膜下纤维化患者被随机分为A组和B组。A组患者接受安慰剂,而B组患者接受400毫克己酮可可碱,为期7个月。根据症状和体征评分的改善情况评估治疗结果。采用学生t检验比较结果。

结果

A组总(即症状+体征)评分改善率为25%,B组为49.15%。发现这种差异具有统计学意义(p<0.05)。

结论

B组治疗方案更有效。未观察到明显副作用。需要进行随访研究以评估该疗法的长期效果。

相似文献

1
Pentoxifylline therapy in the management of oral submucous fibrosis.己酮可可碱疗法在口腔黏膜下纤维化治疗中的应用
Asian Pac J Cancer Prev. 2011;12(4):971-4.
2
"Introducing Modified Dakkak and Bennett Grading System for Indian Food in Oral Submucous Fibrosis": A Dharwad Study.《印度口腔黏膜下纤维化中改良的达卡克和贝内特印度食物分级系统介绍》:一项达沃研究
J Diet Suppl. 2019;16(2):207-214. doi: 10.1080/19390211.2018.1448922. Epub 2018 Apr 6.
3
Efficacy of hydrocortisone acetate/hyaluronidase vs triamcinolone acetonide/hyaluronidase in the treatment of oral submucous fibrosis.醋酸氢化可的松/透明质酸酶与曲安奈德/透明质酸酶治疗口腔黏膜下纤维性变的疗效比较。
Indian J Med Res. 2010 May;131:665-9.
4
Efficacy of lycopene in the management of oral submucous fibrosis.番茄红素在口腔黏膜下纤维化治疗中的疗效。
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Feb;103(2):207-13. doi: 10.1016/j.tripleo.2006.07.011. Epub 2006 Oct 24.
5
Pentoxifylline - A Novel Adjunct in the Management of Patients with Oral Submucous Fibrosis in Terai Population of Nepal: A Prospective Case Control Study.己酮可可碱 - 尼泊尔台拉地区口腔黏膜下纤维性变患者治疗的新辅助药物:一项前瞻性病例对照研究。
Mymensingh Med J. 2022 Oct;31(4):1170-1178.
6
Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis.己酮可可碱疗法:口腔黏膜下纤维化治疗的一种新辅助方法。
Indian J Dent Res. 2006 Oct-Dec;17(4):190-8. doi: 10.4103/0970-9290.29865.
7
Effect of α-tocopherol on salivary reactive oxygen species and trace elements in oral submucous fibrosis.α-生育酚对口腔黏膜下纤维性变唾液中活性氧和微量元素的影响。
Ann Clin Biochem. 2012 May;49(Pt 3):262-5. doi: 10.1258/acb.2011.011050. Epub 2012 Feb 15.
8
Evaluating the efficacy of pentoxifylline in the treatment of oral submucous fibrosis: A meta-analysis.评价己酮可可碱治疗口腔黏膜下纤维性变的疗效:一项荟萃分析。
Oral Dis. 2018 Jul;24(5):706-716. doi: 10.1111/odi.12715. Epub 2017 Aug 22.
9
Oral submucous fibrosis: an overview of the aetiology, pathogenesis, classification, and principles of management.口腔黏膜下纤维化:病因、发病机制、分类及治疗原则概述
Br J Oral Maxillofac Surg. 2013 Oct;51(7):587-93. doi: 10.1016/j.bjoms.2012.08.014. Epub 2012 Oct 26.
10
Oral squamous cell carcinoma arising in background of oral submucous fibrosis: a clinicopathologically distinct disease.口腔黏膜下纤维性变背景下发生的口腔鳞状细胞癌:一种临床病理特征明显不同的疾病。
Head Neck. 2013 Oct;35(10):1404-9. doi: 10.1002/hed.23143. Epub 2012 Sep 13.

引用本文的文献

1
Interventions for managing oral submucous fibrosis.口腔黏膜下纤维性变的处理干预。
Cochrane Database Syst Rev. 2024 Feb 28;2(2):CD007156. doi: 10.1002/14651858.CD007156.pub3.
2
Comparison of Intralesional Placentrex Versus Hyaluronidase and Dexamethasone Injection in the Symptomatic Management of Stage II Oral Submucous Fibrosis - a Prospective Study.病灶内注射胎盘组织液与透明质酸酶及地塞米松注射治疗II期口腔黏膜下纤维化症状的比较——一项前瞻性研究
Indian J Otolaryngol Head Neck Surg. 2023 Dec;75(4):3530-3534. doi: 10.1007/s12070-023-04016-5. Epub 2023 Jul 4.
3
Drug treatment for oral submucous fibrosis: an update.
口腔黏膜下纤维性变的药物治疗:最新进展。
BMC Oral Health. 2023 Oct 12;23(1):748. doi: 10.1186/s12903-023-03488-9.
4
Evaluation of Clinical Profile and Various Treatment Modalities in Oral Sub Mucous Fibrosis in North India: Our Experience.印度北部口腔黏膜下纤维化的临床特征及各种治疗方式评估:我们的经验
Indian J Otolaryngol Head Neck Surg. 2022 Dec;74(Suppl 3):6313-6320. doi: 10.1007/s12070-021-03049-y. Epub 2022 Jan 8.
5
Comparative Efficacy of Interventions for the Management of Oral Submucous Fibrosis: A Systematic Review and Network Meta-Analysis.口腔黏膜下纤维化管理干预措施的比较疗效:一项系统评价与网状Meta分析
J Pers Med. 2022 Aug 1;12(8):1272. doi: 10.3390/jpm12081272.
6
Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.抗纤维化治疗在狭窄型克罗恩病中的发展:其他纤维化疾病随机试验的经验教训。
Physiol Rev. 2022 Apr 1;102(2):605-652. doi: 10.1152/physrev.00005.2021. Epub 2021 Sep 27.
7
Potential Application of an Aqueous Extract of (Thunb.) Miers (Giloy) in Oral Submucous Fibrosis-An In Vitro Study.(千金藤属植物)米尔氏(吉洛依)水提取物在口腔黏膜下纤维化中的潜在应用——一项体外研究
Materials (Basel). 2021 Jun 18;14(12):3374. doi: 10.3390/ma14123374.
8
Medicinal management of oral submucous fibrosis in the past decade- A systematic review.过去十年口腔黏膜下纤维化的药物治疗——一项系统综述
J Oral Biol Craniofac Res. 2020 Oct-Dec;10(4):552-568. doi: 10.1016/j.jobcr.2020.08.004. Epub 2020 Aug 19.
9
An immunohistochemical study of p53 expressions in oral submucous fibrosis.口腔黏膜下纤维化中p53表达的免疫组织化学研究
J Oral Maxillofac Pathol. 2019 May-Aug;23(2):308. doi: 10.4103/jomfp.JOMFP_277_17.
10
Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases.尼达尼布和其他潜在抗纤维化药物在纤维化疾病中的应用。
Clin Sci (Lond). 2019 Jun 19;133(12):1309-1320. doi: 10.1042/CS20190249. Print 2019 Jun 28.